Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYuqin SongCapital Medical UniversityMJMing JiangGuangxi Normal UniversityXSXiuhua SunDalian Medical University

Discussion

Loading...

Member takes

Overview

Phase 1 trial shows rocbrutinib achieves 89.3% response rate in BTKi-naïve mantle cell lymphoma, suggesting favorable safety and efficacy profile.

Key Points

  • To evaluate the efficacy and safety of rocbrutinib in patients with relapsed/refractory mantle cell lymphoma.
  • Phase 1 trial evaluating rocbrutinib monotherapy in patients with relapsed/refractory MCL
  • Patients aged 18–80 who received at least one prior therapy were included
  • Efficacy assessed by Lugano 2014 criteria, adverse events graded by CTCAE v5.0
  • Overall response rate was 89.3%, with a complete response rate of 57.1%
  • Median follow-up period was 21.2 months
  • 18-month progression-free survival rate was 74.3%
  • Common treatment-related adverse events included decreased neutrophil and platelet counts

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9dahttps://doi.org/10.1182/blood-2025-3587
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial2025 · 1 citations
  2. 2Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)2025 · 3 citations
  3. 3Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor2025 · 2 citations
  4. 4Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study2025 · 7 citations
  5. 5ROCK-2: An ongoing open-label, randomized, multicenter phase 2 study of rocbrutinib versus investigator's choice of therapy in patients with R/R non-GCB DLBCL.2026